A study published in Clinical Lung Cancer finds that 93% of oncologists adjust their treatment recommendations with the help of PROphetNSCLC, a test developed by Israel’s OncoHost (see here previously). https://www.ourcrowd.com/startup-news/clinical-lung-cancer-publishes-study-93-of-oncologists-adjust-treatment-recommendations-with-oncohosts-prophetnsclc-test https://www.clinical-lung-cancer.com/article/S1525-7304(24)00138-4/fulltext

A trial of the PROphet blood test from Israel’s OncoHost (see here previously) has proved its accuracy and reliability in predicting the best treatment for metastatic non-small cell lung cancer (NSCLC) patients. OncoHost has received orders from 29 US cancer … Continue reading →

Ben-Gurion University researchers have partnered Israel’s OncoHost to develop a biosensor that safely predicts if anti-PD1 therapy may cure a specific cancer patient. The leading immune checkpoint inhibitor (ICI) therapy is invasive and other treatments may be better. (see also … Continue reading →

Israel’s OncoHost (see here previously) has opened a new laboratory in North Carolina for its PROphet blood test to identify which cancer treatments are likely to work. Israeli Nobel Prize winner Aaron Ciechanover is an OncoHost’s advisor. PROphet may also … Continue reading →

The UK National Health Service (NHS) is to trial the blood test from Israel’s OncoHost (see here previously) that predicts how well cancer patients will respond to immunotherapy treatment. Trials will focus on patients with advanced melanoma or non-small cell … Continue reading →

Israel’s OncoHost (reported here previously) has achieved about 90% accuracy in predicting how melanoma and lung cancer patients respond to various therapies. And now Israeli Nobel Prize winner Professor Aaron Ciechanover has joined OncoHost’s scientific advisory board. https://www.prnewswire.com/il/news-releases/oncohost-welcomes-nobel-prize-winner-to-scientific-advisory-board-301205142.html https://jitc.bmj.com/content/8/Suppl_3/A11.2 https://www.timesofisrael.com/spotlight/nobel-prizewinner-ciechanover-hails-much-more-precise-cancer-treatment/ … Continue reading →

Israel’s Oncohost (reported here previously) presented the results of its latest proteomic (proteins) cancer study to the Society for Immunotherapy of Cancer’s (SITC). Oncohost’s PROphet host response profiling platform can predict the best therapy to use for specific cancer patients. … Continue reading →

Israel’s Oncohost is working with Israel’s Technion to develop cutting-edge technology to characterize, analyze and predict patient response and resistance to cancer therapy. This enables personalized treatment strategies with improved outcomes & reduced side effects. http://oncohost.com/ https://www.jpost.com/Jpost-Tech/Hillels-Tech-Corner-Cancer-treatment-personalized-610032